Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Supernus Pharm (NQ: SUPN ) 27.12 +0.55 (+2.07%) Official Closing Price Updated: 4:15 PM EDT, May 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Supernus Pharm < Previous 1 2 3 4 Next > Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference May 30, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy May 23, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures May 09, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Recap: Supernus Pharmaceuticals Q4 Earnings February 27, 2024 Via Benzinga Earnings Scheduled For February 27, 2024 February 27, 2024 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. Via Benzinga Supernus Pharmaceuticals: Q3 Earnings Insights November 08, 2023 Via Benzinga SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024 May 08, 2024 SUPN stock results show that Supernus Pharmaceuticals missed on revenue for the first quarter of 2024. Via InvestorPlace Supernus Announces First Quarter 2024 Financial Results May 08, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors May 02, 2024 From Glancy Prongay & Murray LLP Via Business Wire INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors May 01, 2024 From Law Offices of Howard G. Smith Via Business Wire Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story May 01, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors April 29, 2024 From The Law Offices of Frank R. Cruz Via Business Wire Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 April 24, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease April 08, 2024 Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830, an investigational apomorphine infusion device for Parkinson's disease. CRL indicates additional review needed for product... Via Benzinga Exposures Product Safety 12 Health Care Stocks Moving In Monday's Pre-Market Session April 08, 2024 Via Benzinga Supernus Provides Regulatory Update for SPN-830 April 08, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Biotechnology And Healthcare, A Bit Of A Lull March 25, 2024 Strong momentum of Tech and Chip stocks may be too good of a distraction for biotech investors. Via Talk Markets Supernus to Participate in Two Upcoming Investor Conferences March 06, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference February 28, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces Fourth Quarter and Full Year 2023 Financial Results February 27, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024 February 13, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent February 05, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential December 14, 2023 The increased understanding and widespread acceptance of mental health concerns have put psychedelic stocks in the spotlight. Via InvestorPlace Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings December 12, 2023 Consumer advocacy group Public Citizen has filed a petition with the FDA, urging the agency to demand stronger warnings regarding the risk of a potentially fatal muscle-paralyzing disease linked to... Via Benzinga Exposures Product Safety Supernus Announces Third Quarter 2023 Financial Results November 08, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Earnings Scheduled For November 8, 2023 November 08, 2023 Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter. Via Benzinga Supernus to Participate in the Jefferies London Healthcare Conference November 07, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA November 02, 2023 PDUFA Target Action Date of April 5, 2024 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023 October 25, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey October 16, 2023 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.